Now available on demand. Sign up to view

Circulating Tumour Cells: Liquid biopsy by high-throughput, high-resolution imaging flow cytometry

Originally aired; March 28, 2017

Circulating tumour cells (CTCs) have the potential to act as a source of tumour tissue for the measurement of pharmacodynamic biomarkers in early phase clinical trials. This is particularly the case in settings where the need for pharmacodynamic data do not justify the risk or inconvenience to the patients in taking biopsies. In this respect assays for the characterisation of CTCs need to move beyond enumeration alone and take heterogeneity into account.
 
This webcast will describe the sample processing, data collection and data analysis used by Dr. David Jamieson to characterise CTCs by imaging flow cytometry. There will also be a focus on clinical data acquired with his methodology, from a cohort of patients with hepatocellular carcinoma, and a discussion on approaches to incorporating pharmacodynamic biomarker assays into the method.

In this webcast you will learn:

• How imaging flow cytometry is applied to identify circulating tumour cells
• The importance of using multiple biomarkers for CTC detection
• Data will be discussed supporting the applicability of the method as a liquid biopsy tool for hepatocellular carcinoma patients
• The applicability of the method to all tumour types